Valeant's Legal Woes Aren't New, but They Are Mounting

Image source: Getty Images.

Continue Reading Below

On the heels of a dramatic post-second quarter earnings run-up in shares, reportsValeant Pharmaceuticals (NYSE: VRX) investors back on the defense again. The reports of investigations into the company's use of Philidor (a specialty pharmacy it was closely tied to) aren't new, but the number of investigations does appear to be increasing, and that adds uncertainty to a story that was already pretty uncertain.

Smoke and fire?

Valeant Pharmaceuticals isn't hiding the various investigations into it from investors. In fact, the company's recently filed quarterly 10-Q with the Securities and Exchange Commission discloses an unfortunately long list of investigations into its past, including these low-lights:

Continue Reading Below

<3>More From